Zobrazeno 1 - 10
of 27
pro vyhledávání: ''
Autor:
Weiqiang Zhao, Mahmoud Abdel-Rasoul, Desmond M. D’Souza, David P. Carbone, Robert E. Merritt, Dan Jones, Peter J. Kneuertz, Terrance M. Williams, Konstantin Shilo
Publikováno v:
Lung Cancer. 143:60-66
This study aimed to evaluate the prognostic and potential therapeutic value of expanded molecular testing of resected early-stage lung ACA.We analyzed 324 patients who underwent lobectomy and lymphadenectomy for clinical Stage III lung ACA between 20
Autor:
Anke Behnke, Denise Treue, Philipp Jurmeister, Leonille Schweizer, Maximilian von Laffert, Claudia Vollbrecht, Nikolaj Frost, Jens-Carsten Rückert, David Horst, Jens Neudecker, Frederick Klauschen, Manfred Dietel, Alexander Arnold, Michael Hummel
Publikováno v:
Lung Cancer. 138:43-51
Objectives We aim to provide a better understanding of the molecular landscape of primary lung adenocarcinomas with intestinal differentiation. Material and Methods Five invasive mucinous adenocarcinomas (IMA) and seven pulmonary enteric adenocarcino
Publikováno v:
Lung Cancer. 135:116-122
Objectives The utility of malignant pleural effusion (MPE) as a source for determining EGFR mutations to guide EGFR TKI therapy in advanced adenocarcinoma of the lung remains unclear. This study compared MPE, plasma and tumor tissues as sources of bi
Autor:
Xue Wu, Yang W. Shao, Qiuxiang Ou, Junrong Yan, Jun Zhao, Ying Jin, Xinmin Yu, Xun Shi, Qiong He, Ming Chen
Publikováno v:
Lung Cancer. 124:110-116
Introduction Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma with EGFR mutations may impact clinical responses and outcomes to EGFR tyrosine kinase inhibitor (TKI) treatments. Methods We performed ge
Autor:
H. Henry Guo, Christian A. Kunder, Joel W. Neal, Samantha X Y Wang, Li Lei, Joseph B. Shrager
Publikováno v:
Lung Cancer. 122:187-191
When a patient is found to have multiple lung tumors, distinguishing whether they represent metastatic nodules or separate primary cancers is crucial for staging and therapy. We report the case of a 79-year-old patient with two surgically resected sy
Autor:
Chantal C H J Kuijpers, Stefan M. Willems, Jules L. Derks, Ronald A M Damhuis, M. van den Heuvel, Lizza E.L. Hendriks, A. Van Lindert, Anne-Marie C. Dingemans
Publikováno v:
Lung Cancer, 121, 76. Elsevier Ireland Ltd
Lung Cancer, 121, pp. 76-81
Lung Cancer, 121, 76-81
Lung Cancer, 121, 76-81. Elsevier Ireland Ltd
Lung Cancer, 121, 76-81. ELSEVIER IRELAND LTD
Lung Cancer, 121, pp. 76-81
Lung Cancer, 121, 76-81
Lung Cancer, 121, 76-81. Elsevier Ireland Ltd
Lung Cancer, 121, 76-81. ELSEVIER IRELAND LTD
Contains fulltext : 193662.pdf (Publisher’s version ) (Open Access) OBJECTIVES: Biological predisposition for specific metastatic organs might differ between molecular subgroups of lung cancer. We aimed to assess the association between molecular s
Publikováno v:
Lung Cancer. 102:101-107
Objectives Activating mutations in the epidermal growth factor receptor (EGFR) are strongly predictive of EGFR-tyrosine kinase inhibitor (TKI) activity in non-small cell lung cancer (NSCLC). However, primary resistance to EGFR-TKIs occurs in approxim
Publikováno v:
Lung Cancer. 102:82-88
Introduction An invasive mucinous adenocarcinoma (IMA) is a distinct lung adenocarcinoma variant. The characteristics of stage IV IMAs are relatively unclear since most previous studies described resected cases from stage I to III. The present study
Autor:
Chi Ren Tsai, Cheng-Ta Yang, Tsung-Ying Yang, Jeng-Sen Tseng, Gee-Chen Chang, Chih-Liang Wang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Chih Yi Chen
Publikováno v:
Lung Cancer. 90:472-476
Smoking status is an important determinant of the prevalence of epidermal growth factor receptor (EGFR) mutations in lung cancer patients. However, it is unclear whether smoking status could also influence the spectrum of EGFR mutations.We enrolled p
Autor:
Paul A. VanderLaan, Scott R. Floyd, Deepa Rangachari, Anand Mahadevan, Mark S. Huberman, Suzanne E. Dahlberg, Norihiro Yamaguchi, Eric S. Wong, Daniel B. Costa, Erik J. Uhlmann, Erik Folch
Publikováno v:
Lung Cancer. 88:108-111
Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC). However, the baseline incidence and evolution of BM over time in oncogene-driven NSCLCs are seldom reported. In this study, we evaluated the frequency of BM in patients with epid